Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Continuing Medical Education

CME: L’hypertension artérielle et la pandémie COVID-19: Ce qu’il faut retenir en pratique médicale

Published Online:February 02, 2021https://doi.org/10.1024/1661-8157/a003639

Abstract

Résumé. La pandémie COVID-19 représente un problème de santé publique majeur. Une partie de la population est à risque accru de développer des complications de cette maladie, en particulier les personnes âgées ainsi que les malades diabétiques, les obèses et, possiblement, les malades hypertendus. Pour ces derniers, cela reste à être confirmé dans des études contrôlées de grande envergure. Les connaissances accumulées à ce jour sont rassurantes, que les malades soient traités ou non. Il n’y a pas de crainte à avoir en ce qui concerne la prise de médicaments antihypertenseurs, y compris les bloqueurs du système rénine-angiotensine. Les premières observations indiquent que le vaccin anti-COVID-19 peut être administré chez le malade hypertendu avec la meme efficacité que le normotendu. En conclusion il n’y a pas de raison de prendre en charge le malade hypertendu autrement qu’avant l’apparition de la pandémie.


CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice

Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.

Bibliographie

  • Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87(5):E1–E9. First citation in articleCrossref Medline, Google Scholar

  • Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020. First citation in articleCrossref, Google Scholar

  • Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828. First citation in articleCrossref Medline, Google Scholar

  • Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. First citation in articleCrossref Medline, Google Scholar

  • Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3(4):e205619. First citation in articleGoogle Scholar

  • Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. First citation in articleGoogle Scholar

  • Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581. First citation in articleGoogle Scholar

  • Gottlieb M, Sansom S, Frankenberger C, Ward E, Hota B. Clinical course and factors associated with hospitalization and critical illness among COVID-19 patients in Chicago, Illinois. Acad Emerg Med 2020;27(10):963–973. First citation in articleCrossref Medline, Google Scholar

  • Matsushita K, Ding N, Kou M, et al. The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis. Glob Heart. 2020;15(1):64. First citation in articleCrossref Medline, Google Scholar

  • Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi: 10.1177/1470320320926899. First citation in articleCrossref, Google Scholar

  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. First citation in articleGoogle Scholar

  • Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. First citation in articleCrossref, Google Scholar

  • Yanover C, Mizrahi B, Kalkstein N, et al. What Factors Increase the risk of complications in SARS-CoV-2-infected patients? A cohortstudy in a nationwide Israeli health organization. JMIR Public Health Surveill. 2020;6(3):e20872. First citation in articleCrossref Medline, Google Scholar

  • Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81(2):e16–e25. First citation in articleCrossref Medline, Google Scholar

  • Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2224–2230. First citation in articleCrossref Medline, Google Scholar

  • Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. First citation in articleCrossref Medline, Google Scholar

  • Bonner C, Cvejic E, Ayre J, et al. Impact of COVID-19 restrictions on people with hypertension. medRxiv. 2020;2020. 10.12.20211722. First citation in articleCrossref, Google Scholar

  • Czeisler ME, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic – United States, June 24– 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049–1057. First citation in articleGoogle Scholar

  • Ran J, Song Y, Zhuang Z, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;​43(11):1267–1276. First citation in articleCrossref Medline, Google Scholar

  • Sheppard JP, Nicholson B, Lee J, et al. The association between blood pressure control and coronavirus disease 2019 outcomes in 45,418 symptomatic patients with hypertension: An observational cohort study. Hypertension. 2020 Dec 16. doi: 10.1161/HYPERTENSIONAHA.120.16472. Epub ahead of print. PMID: 33325240. First citation in articleGoogle Scholar

  • Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168–1677. First citation in articleCrossref Medline, Google Scholar

  • Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–2448. First citation in articleCrossref Medline, Google Scholar

  • Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020. First citation in articleCrossref, Google Scholar

  • Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N EnglJ Med. 2020. First citation in articleCrossref, Google Scholar

  • Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058–2066. First citation in articleCrossref Medline, Google Scholar

  • Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106(19):1503–1511. First citation in articleCrossref Medline, Google Scholar

  • Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv. 2020; 2020.03.20.20039586. First citation in articleGoogle Scholar

  • Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. First citation in articleCrossref Medline, Google Scholar

  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 Vaccine. N Engl J Med. 2020. First citation in articleCrossref, Google Scholar

  • Krittanawong C, Kumar A, Hahn J, et al. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis. 2020;10(4):479–489. First citation in articleMedline, Google Scholar

  • Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther. 2020;107750. First citation in articleGoogle Scholar